Market news

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clinic

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clin

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Detailed price information for Altimmune Inc (ALT-Q) from The Globe and Mail including charting and trades.

Altimmune reports positive Phase 2 AUD data and rapid progress in its MASH Phase 3 trial, backed by $519 million in cash.

Altimmune (NASDAQ:ALT) said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD. Chairman and Chief Executive Office

Moby summary of Altimmune, Inc.'s Q2 2026 earnings call

Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced fina

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on August 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Inv

Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes Initiation marks advancement of Altimmune's lead program into late-stage development following positive IMPACT Phase 2b data GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced that the company has begun enrolling patients in the PERFORMA Phase

Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an EOP2 meeting with the FDA.

Altimmune Inc. (NASDAQ:ALT) shares climbed 18% on Tuesday after the biotechnology company reported positive topline data from its Phase 2 RECLAIM study evaluating pemvidutide as a treatment for alcohol use disorder.

Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which are recognized by the FDA as registrational endpoints A generally favorable tolerability profile was observed in the trial Conference call to be held today at 8:00 am ET GAITHERSBURG, Md., July 28, 2026

I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Altimmune (ALT).

Earlier on Tuesday, Altimmune said the mid-stage RECLAIM trial met its main goal and key secondary goals.

Altimmune’s Phase 2 trial showed Pemvidutide reduced heavy drinking by 4.20 days per week compared with the placebo’s 2.75 days.

Altimmune (NASDAQ:ALT) reported positive top-line results from its Phase II RECLAIM trial evaluating pemvidutide in adults with moderate to severe alcohol use disorder, or AUD, with the company saying the study met its primary endpoint and several secondary measures after 24 weeks of treatment. The

Altimmune, Inc. (NASDAQ:ALT), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. Fresh analyst confidence in the company’s MASH drug candidate follows strong data that continues to build the case for pemvidutide. On June 22, 2026, Leerink analyst Thomas Smith initiated coverage of Altimmune, Inc. (NASDAQ:ALT) with an “Outperform” […]